Molecular Oncology

Papers
(The median citation count of Molecular Oncology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Issue Information124
114
Issue Information108
91
Issue Information78
Transcriptome‐wide analysis of circRNA and RBP profiles and their molecular relevance for GBM75
Corrigendum to: Small proline‐rich repeat protein 3 enhances the sensitivity of esophageal cancer cells in response to DNA damage‐induced apoptosis70
Microglia limit brain tumor development by restricting tumor cell proliferation and inducing T‐cell immunity67
Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type‐B receptor 466
Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling62
Development of an optimized, non‐stem cell line for intranasal delivery of therapeutic cargo to the central nervous system60
Gene signature predicting recurrence in oral squamous cell carcinoma is characterized by increased oxidative phosphorylation50
PoDCall: a robust tool for automated droplet classification in DNA‐methylation droplet digital PCR48
47
Correction to “SPT6 recruits SND1 to co‐activate human telomerase reverse transcriptase to promote colon cancer progression”46
The multispecies microbial cluster of Fusobacterium, Parvimonas, Bacteroides and Faecalibacterium as a precision biomarker for colorectal cancer diagnosis45
Precision Cancer Medicine 2.0—Oncology in the postgenomic era41
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma40
The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer37
Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti‐CD73/anti‐PDL1 immunotherapy in arm A of the NSGO36
Interaction between membranous EBP50 and myosin 9 as a favorable prognostic factor in ovarian clear cell carcinoma35
TGFβ selects for pro‐stemness over pro‐invasive phenotypes during cancer cell epithelial–mesenchymal transition34
Cancer‐associated fibroblasts educate normal fibroblasts to facilitate cancer cell spreading and T‐cell suppression34
Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1NDRG1 deregulation34
Whole‐genome sequencing of cell‐free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas33
NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy30
Correction to “Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition”30
Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy30
An arms‐race against resistance: leukemic stem cells and lineage plasticity29
Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancer29
Unraveling the metastasis‐preventing effect of miR‐200c in vitro and in vivo29
Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient‐derived orthotopic xenografts, cell lines and tumor entities28
Nanosecond pulsed electric field ablation‐induced modulation of sphingolipid metabolism is associated with Ly6c2+ mononuclear phagocyte differentiation in liver cancer28
Ovarian cancer relies on the PDGFRβ–fibronectin axis for tumorsphere formation and metastatic spread28
RETRACTION: Long Noncoding RNA ZNF667‐AS1 Reduces Tumor Invasion and Metastasis in Cervical Cancer by Counteracting Microrna‐93‐3p‐Dependent PEG3 Downregulation27
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity27
Evaluation of two new highly multiplexed PCR assays as an alternative to next‐generation sequencing for IDH1/2 mutation detection27
Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF127
Erratum to: Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors27
Lysosome‐dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer27
Exosomes secreted by ST3GAL5high cancer cells promote peritoneal dissemination by establishing a premetastatic microenvironment27
Issue Information25
Germline variants in CDKN2A wild‐type melanoma prone families25
Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient‐derived xenograft models25
Hijacking the BAF complex: the mechanistic interplay of ARID1A and EWS::FLI1 in Ewing sarcoma25
New retinoblastoma (RB) drug delivery approaches: anti‐tumor effect of atrial natriuretic peptide (ANP)‐conjugated hyaluronic‐acid‐coated gold nanoparticles for intraocular treat25
Trapping all ERBB ligands decreases pancreatic lesions in a murine model of pancreatic ductal adenocarcinoma25
Correction to: Clinical and biological relevance of the transcriptomic‐based prostate cancer metastasis subtypes MetA‐C24
Academia and society should join forces to make anti‐cancer treatments more affordable24
Cancer cachexia: biomarkers and the influence of age24
Proteome‐based molecular subtyping and therapeutic target prediction in gastric cancer24
ANGPTL2‐mediated epigenetic repression of MHC‐I in tumor cells accelerates tumor immune evasion23
A single gene mutation predicts response to immune checkpoint blockade in ovarian clear cell carcinoma23
Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer23
Disruption of tp53 leads to cutaneous nevus and melanoma formation in Xenopus tropicalis23
RNA polymerase I inhibition induces terminal differentiation, growth arrest, and vulnerability to senolytics in colorectal cancer cells22
Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients22
T2R bitter taste receptors regulate apoptosis and may be associated with survival in head and neck squamous cell carcinoma22
Issue Information22
Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib‐resistant chronic lymphocytic leukaemia22
Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic–mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer22
Glioblastoma and cerebral organoids: development and analysis of an in vitro model for glioblastoma migration22
Retraction statement: Consistency analysis of microRNA‐arm expression reveals microRNA‐369‐5p/3p as tumor suppressors in gastric cancer21
The LIN28B–let‐7–PBK pathway is essential for group 3 medulloblastoma tumor growth and survival21
The transcribed ultraconserved region uc.160+ enhances processing and A‐to‐I editing of the miR‐376 cluster: hypermethylation improves glioma prognosis21
Tetraploidy‐linked sensitization to CENP‐E inhibition in human cells20
Correction to “The polyamine transporter ATP13A3 mediates difluoromethylornithine‐induced polyamine uptake in neuroblastoma”20
LncRNA miR205HG hinders HNRNPA0 translation: anti‐oncogenic effects in esophageal carcinoma20
Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T‐cell receptor sequencing20
A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications19
Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK<19
Issue Information19
DRD1 suppresses cell proliferation and reduces EGFR activation and PD‐L1 expression in NSCLC19
19
NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance by creating a β2AR‐Akt feedback loop that activates autophagy19
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma19
Replenishing co‐downregulated miR‐100‐5p and miR‐125b‐5p in malignant germ cell tumors causes growth inhibition through cell cycle disruption19
Sustained cancer‐relevant alternative RNA splicing events driven by PRMT5 in high‐risk neuroblastoma18
Issue Information18
Serine protease inhibitors decrease metastasis in prostate, breast, and ovarian cancers18
17
Functional loss of ERBB receptor feedback inhibitor 1 (MIG6) promotes glioblastoma tumorigenesis by aberrant activation of epidermal growth factor receptor (EGFR)17
Post‐prostatic‐massage urine exosomes of men with chronic prostatitis/chronic pelvic pain syndrome carry prostate‐cancer‐typical microRNAs and activate proto‐oncogenes17
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting17
Cancer outcome research – a European challenge Part II: Opportunities and priorities17
MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness17
Correction to “The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion”17
SETD2 loss in renal epithelial cells drives epithelial‐to‐mesenchymal transition in a TGF‐β‐independent manner17
FGF7–FGFR2 autocrine signaling increases growth and chemoresistance of fusion‐positive rhabdomyosarcomas16
RNA cytosine methyltransferase NSUN5 promotes protein synthesis and tumorigenic phenotypes in glioblastoma16
Prognostic association of immunoproteasome expression in solid tumours is governed by the immediate immune environment16
DNA repair as a shared hallmark in cancer and ageing16
Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models16
Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR<16
Ubiquitination of transcription factors in cancer: unveiling therapeutic potential16
Cancer as an infective disease: the role of EVs in tumorigenesis16
Mcl‐1 and Bcl‐xL levels predict responsiveness to dual MEK/Bcl‐2 inhibition in B‐cell malignancies16
Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients16
CHML is an NRF2 target gene that regulates mTOR function16
Long noncoding RNAs with peptide‐encoding potential identified in esophageal squamous cell carcinoma: KDM4A‐AS1‐encoded peptide weakens cancer cell viability and migratory capacity16
Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models16
Targeting protein folding in N‐Myc‐driven medulloblastoma16
PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism16
Rodent models of tumours of the central nervous system16
Lipidomic profiling of exosomes from colorectal cancer cells and patients reveals potential biomarkers16
Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel16
Abstracts16
Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience15
Assembly of glioblastoma tumoroids and cerebral organoids: a 3Din vitro model for tumor cell invasion15
Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation15
A rapid, multiplex digital PCR assay to detect gene variants and fusions in non‐small cell lung cancer15
Lung cancer cells expressing a shortened CDK16 3′UTR escape senescence through impaired miR‐485‐5p targeting15
KRAS inhibitors: going noncovalent15
Assay‐agnostic spatial profiling detects tumor microenvironment signatures: new diagnostic insights for triple‐negative breast cancer15
Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer15
Issue Information14
A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL‐13Rα2‐mediated JNK‐AP‐1 signals14
14
Atezolizumab and stereotactic body radiotherapy in patients with advanced non‐small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT‐1 trial14
cAMP‐phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression14
PP2A‐based triple‐strike therapy overcomes mitochondrial apoptosis resistance in brain cancer cells14
Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach14
Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7 ‐mutated 14
Retraction Statement: Circ‐TCF4.85 silencing inhibits cancer progression through microRNA‐486‐5p‐targeted inhibition of ABCF2 in hepatocellular carcinoma14
Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B114
PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis14
Simultaneous detection of eight cancer types using a multiplex droplet digital PCR assay14
Highly multiplexed digital PCR assay for simultaneous quantification of variant allele frequencies and copy number alterations of KRAS and GNAS in pancreatic cancer precursors14
Issue Information14
Elucidating prognostic significance of purine metabolism in colorectal cancer through integrating data from transcriptomic, immunohistochemical, and single‐cell RNA sequencing analysis14
Liver X receptors induce antiproliferative effects in basal‐like breast cancer14
The correlation between clinical outcomes and genomic analysis with high risk factors for the progression of osteosarcoma14
Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells13
Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer13
SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma13
Microglia and macrophages in glioblastoma: landscapes and treatment directions13
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma13
Targeting senescence as an anticancer therapy13
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs13
In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma13
Targeting cellular senescence to combat cancer and ageing13
Crosstalk between gut microbiota and tumor: tumors could cause gut dysbiosis and metabolic imbalance13
SKA1 promotes oncogenic properties in oral dysplasia and oral squamous cell carcinoma, and augments resistance to radiotherapy12
Copy number variations contribute to malignant tumor development in children with serious birth defects12
Lipid metabolism in B cell biology12
Issue Information12
Protein palmitoylation in cancer: molecular functions and therapeutic potential12
Thioredoxin‐interacting protein (TXNIP) is a substrate of the NEDD4‐like E3 ubiquitin‐protein ligase WWP1 in cellular redox state regulation of acute myeloi12
Enhanced reversal of ABCG2‐mediated drug resistance by replacing a phenyl ring in baicalein with a meta‐carborane12
Plasma extrachromosomal circular DNA as a biomarker in EGFR ‐targeted therapy of non‐small cell lu12
Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome12
Postbiotics of Lacticaseibacillus paracaseiCECT 9610 and Lactiplantibacillus plantarumCECT 9608 attenuates store‐operated calcium entry and FAK phosphory12
Loss of Lkb1 cooperates with BrafV600E and ultraviolet radiation, increasing melanoma multiplicity and neural‐like dedifferentiation12
Issue Information12
Issue Information12
Immune evasion: An imperative and consequence of MYC deregulation11
Fragment‐based drug discovery—the importance of high‐quality molecule libraries11
ARID1A‐deficient cells require HDAC6 for progression of endometrial carcinoma11
From bedside to portable and wearable: development of a conformable ultrasound patch for deep breast tissue imaging11
SMG1, a nonsense‐mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma11
The invariant chain CD74 protein is a cell surface binding partner of TIMP‐1 in breast cancer cells11
11
Expression of Concern: T‐LAK cell‐originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma11
CircCCNB1 inhibits vasculogenic mimicry by sequestering NF90 to promote miR‐15b‐5p and miR‐7‐1‐3p processing in nasopharyngeal carcinoma11
Metabolism in the tumor cell and beyond11
Current status of precision oncology in adult glioblastoma11
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients11
11
Issue Information11
Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia11
The polyamine transporter ATP13A3 mediates difluoromethylornithine‐induced polyamine uptake in neuroblastoma11
Immune escape of colorectal tumours via local LRH‐1/Cyp11b1‐mediated synthesis of immunosuppressive glucocorticoids11
Comparative membrane lipidomics of hepatocellular carcinoma cells reveals diacylglycerol and ceramide as key regulators of Wnt/β‐catenin signaling and tumor growth11
GALNT2 promotes invasiveness of colorectal cancer cells partly through AXL11
11
Conditional ERK3 overexpression cooperates with PTEN deletion to promote lung adenocarcinoma formation in mice11
The critical role of DNA damage‐inducible transcript 4 (DDIT4) in stemness character of leukemia cells and leukemia initiation10
Integrated analysis of racial disparities in genomic architecture identifies a trans‐ancestry prognostic subtype in bladder cancer10
Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy10
Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis10
Bovine meat and milk factor protein expression in tumor‐free mucosa of colorectal cancer patients coincides with macrophages and might interfere with patient survival10
The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer10
Beyond cytotoxic T cells: reprogrammed regulatory T cells help facilitate response to dual checkpoint blockade10
Ribosome biogenesis‐based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTOR10
LIM domain‐containing protein Ajuba inhibits chemotherapy‐induced apoptosis by negatively regulating p53 stability in colorectal cancer cells10
Identifying the personalized driver gene sets maximally contributing to abnormality of transcriptome phenotype in glioblastoma multiforme individuals10
Identification and targeting of a HES1‐YAP1‐CDKN1C functional interaction in fusion‐negative rhabdomyosarcoma10
Thermal proteome profiling and proteome analysis using high‐definition mass spectrometry demonstrate modulation of cholesterol biosynthesis by next‐generation galeterone analog VNPP433‐3β i10
Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker9
Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2‐positive cancers9
Viral mimicry evasion: a new role for oncogenic KRAS mutations9
Inhibition of CDCP1 by 8‐isopentenylnaringenin synergizes with EGFR inhibitors in lung cancer treatment9
Comprehensive profiling of lncRNAs and mRNAs enriched in small extracellular vesicles for early noninvasive detection of colorectal cancer: diagnostic panel assembly and extensiv9
Unlocking the potential of tumor‐derived DNA in urine for cancer detection: methodological challenges and opportunities9
The roles and applications of extracellular vesicles in cancer9
Interferon regulatory factor 4 modulates epigenetic silencing and cancer‐critical pathways in melanoma cells9
Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long‐term follow‐up of the SweBCG91RT rand9
Lipopolysaccharide from the commensal microbiota of the breast enhances cancer growth: role of S100A7 and TLR49
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?9
High CD34 surface expression in BCP‐ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion9
miR‐200a/b/‐429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer9
9
Risk stratification of indeterminate thyroid nodules by novel multigene testing: a study of Asians with a high risk of malignancy9
Unraveling epigenetic heterogeneity across gastrointestinal adenocarcinomas through a standardized analytical framework9
Investigation of somatic mutation profiles and tumor evolution of primary oropharyngeal cancer and sequential lymph node metastases using multiregional whole‐exome sequencing9
Transcriptomic pan‐cancer analysis using rank‐based Bayesian inference9
Nicotinamide (niacin) supplement increases lipid metabolism and ROS‐induced energy disruption in triple‐negative breast cancer: potential for drug repositioning as an anti‐tumor agent9
Ex vivo mapping of enhancer networks that define the transcriptional program driving melanoma metastasis9
Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study9
MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives9
Evaluation of circulating tumor DNA as a prognostic and predictive biomarker in BRAFV600E mutated colorectal cancer—results from the FIRE‐4.5 study9
Levels of circulating tumor DNA correlate with tumor volume in gastro‐intestinal stromal tumors: an exploratory long‐term follow‐up study9
Resistance prediction in high‐grade serous ovarian carcinoma with neoadjuvant chemotherapy using data‐independent acquisition proteomics and an ovary‐specific spectral library9
ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability‐high (MSI‐H) molecular subtype9
Transcription factor 4 is a key mediator of oncogenesis in neuroblastoma by promoting MYC activity9
Oncogenic composite mutations can be predicted by co‐mutations and their chromosomal location9
Plasma membrane SK2 channel activity regulates migration and chemosensitivity of high‐grade serous ovarian cancer cells8
In the spotlight: Julio Celis, the Founding Editor of Molecular Oncology8
Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management8
Metabolism and signaling crosstalk in glioblastoma progression and therapy resistance8
8
Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications8
PP2A methylesterase PME‐1 suppresses anoikis and is associated with therapy relapse of PTEN‐deficient prostate cancers8
Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib8
CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation8
Cell‐free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients8
ITIH5 as a multifaceted player in pancreatic cancer suppression, impairing tyrosine kinase signaling, cell adhesion and migration8
Proximity proteomics reveals role of Abelson interactor 1 in the regulation of TAK1/RIPK1 signaling8
Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia8
Chromosomal instability and a deregulated cell cycle are intrinsic features of high‐risk gastrointestinal stromal tumours with a metastatic potential8
Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer8
Exportin 1‐mediated nuclear/cytoplasmic trafficking controls drug sensitivity of classical Hodgkin's lymphoma8
Deciphering metabolic crosstalk in context: lessons from inflammatory diseases8
Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care8
Flow‐based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product8
The sculpting of somatic mutational landscapes by evolutionary forces and their impacts on aging‐related disease8
PPM1D activity promotes the replication stress caused by cyclin E1 overexpression8
Enhancing therapeutic efficacy in triple‐negative breast cancer and melanoma: synergistic effects of modulated electro‐hyperthermia (mEHT) with NSAIDs especially COX‐2 inhibition in in vivo mod8
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials8
Screening of an annexin‐A2‐targeted heptapeptide for pancreatic adenocarcinoma localization8
Overexpression of the pro‐protein convertase furin predicts prognosis and promotes papillary thyroid carcinoma progression and metastasis through RAF/MEK signaling8
Inhibition of acyl‐CoA synthetase long‐chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction8
A novel pipeline for prioritizing cancer type‐specific therapeutic vulnerabilities using DepMap identifies PAK2 as a target in head and neck squamous cell carcinomas7
Repression of the stress granule protein G3BP2 inhibits immune checkpoint molecule PD‐L17
Machine learning for identifying liver and pancreas cancers through comprehensive serum glycopeptide spectra analysis: a case‐control study7
Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer7
Issue Information7
Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment7
Orthogonal MET analysis in a population‐representative stage II–III colon cancer cohort: prognostic and potential therapeutic implications7
MYC and therapy resistance in cancer: risks and opportunities7
0.08181095123291